GH Research (GHRS) Share-based Compensation (2021 - 2026)
GH Research (GHRS) posted quarterly Share-based Compensation of $2.7 million for Q4 2025, up 249.93% year-over-year from $759000.0 in Q4 2024, and up 15.48% quarter-over-quarter from $2.3 million in Q3 2025.
Analysis
GH Research (GHRS) Share-based Compensation (2021 - 2026) Analysis & Trends
GH Research's Share-based Compensation history runs 5 years deep, the most recent figure standing at $2.7 million for Q4 2025.
- In Q4 2025, Share-based Compensation rose 249.93% year-over-year to $2.7 million; the TTM figure through Dec 2025 stood at $8.5 million (up 586.97% YoY), while the FY2025 annual figure was $13.1 million, up 167.72% from the prior year.
- Share-based Compensation for Q4 2025 stood at $2.7 million, up from $2.3 million in the prior quarter.
- The five-year high for Share-based Compensation was $2.7 million in Q4 2025, with the low at -$100000.0 in Q2 2024.
- The 5-year median for Share-based Compensation is $444000.0 (2022), against an average of $768444.4.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation sank 125.0% in 2024, then jumped 2000.0% in 2025.
- GH Research's Share-based Compensation stood at $269000.0 in 2021, then jumped by 81.41% to $488000.0 in 2022, then surged by 33.4% to $651000.0 in 2023, then grew by 16.59% to $759000.0 in 2024, then soared by 249.93% to $2.7 million in 2025.
- Business Quant data shows GHRS's Share-based Compensation at $2.7 million in Q4 2025, $2.3 million in Q3 2025, and $1.9 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 120.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 277.20 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 137.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 41.25 Mn |
| 10 | GH Research | 1.72 Bn | 1.36 Bn | - | 2.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.20 Mn |
| Mar 31, 2026 | 1.83 Mn |
| Dec 31, 2025 | 2.66 Mn |
| Sep 30, 2025 | 2.30 Mn |
| Jun 30, 2025 | 1.90 Mn |
| Mar 31, 2025 | 1.64 Mn |
| Dec 31, 2024 | 759,000.00 |
| Sep 30, 2024 | 300,000.00 |
| Jun 30, 2024 | -100,000.00 |
| Mar 31, 2024 | 277,000.00 |
| Dec 31, 2023 | 642,000.00 |
| Sep 30, 2023 | 600,000.00 |
| Jun 30, 2023 | 400,000.00 |
| Mar 31, 2023 | 551,000.00 |
| Dec 31, 2022 | 488,000.00 |
| Sep 30, 2022 | 400,000.00 |
| Jun 30, 2022 | 300,000.00 |
| Mar 31, 2022 | 327,000.00 |
| Dec 31, 2021 | 235,000.00 |
| Sep 30, 2021 | 119,000.00 |